Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

December 21st 2023

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma

December 19th 2023

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC

December 19th 2023

An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.

AASLD 2023 Updates: HIMALAYA Trial for uHCC

December 19th 2023

Dr. Saeed outlines the use of combination tremelimumab plus durvalumab in uHCC, discussing updates from the HIMALAYA trial presented at AASLD 2023.

Shitara and Xu Discuss Potential FDA Approval of Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

December 15th 2023

Rui-Hua Xu, MD, PhD, and Kohei Shitara, MD, expand on the advantages of targeting CLDN18.2 with zolbetuximab in gastric/GEJ adenocarcinoma and key efficacy data from the GLOW and SPOTLIGHT trials in support of zolbetuximab’s potential FDA approval.

Intrahepatic Cholangiocarcinoma Overview

December 14th 2023

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.

Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC

December 12th 2023

A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.

The Evolving Landscape of Hepatocellular Carcinoma

December 12th 2023

Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

December 1st 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Educating Community Specialists on Evolving Treatment Landscape

November 24th 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Future Outlook for Treating Breast and Lung Cancers

November 24th 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations

November 21st 2023

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.

Future Directions in Gastric Cancer Treatment

November 17th 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Treatment Considerations With TROP2-Targeted Therapy

November 17th 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Unresectable HER2– Gastric/GEJ Adenocarcinoma

November 16th 2023

The FDA has approved pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

November 14th 2023

China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.

PD-L1 IHC 22C3 pharmDx Gets Green Light From FDA for Determining Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

November 14th 2023

The FDA has approved the PD-L1 IHC 22C3 pharmDx diagnostic tool to aid clinicians in identifying patients with gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment with the PD-1 inhibitor pembrolizumab.

Frontline Pembrolizumab Plus Chemo Approaches EU Approval for Biliary Tract Cancer

November 10th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) combined with gemcitabine and cisplatin in the frontline treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer

TROP2-Targeting Antibody-Drug Conjugates

November 10th 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.